Advances in Low-Concentration Atropine and Optical Interventions for Myopia Control

Weixing Xu , Yan Zhang

Advances in World Medical Research ›› 2026, Vol. 2 ›› Issue (1) : 21 -29.

PDF (164KB)
Advances in World Medical Research ›› 2026, Vol. 2 ›› Issue (1) :21 -29. DOI: 10.71204/h4ject27
research-article
Advances in Low-Concentration Atropine and Optical Interventions for Myopia Control
Author information +
History +
PDF (164KB)

Abstract

Myopia has become a global public health challenge, with its prevalence reaching epidemic proportions in recent decades, particularly in East Asian countries. This comprehensive review synthesizes recent evidence from clinical studies and meta-analyses to examine the efficacy and safety of low-concentration atropine and optical interventions for controlling myopia progression in children and adolescents. We show that low-concentration atropine (specifically 0.01%, 0.025%, and 0.05%) effectively slows myopia progression with a favorable safety profile. Furthermore, we evaluate optical interventions including orthokeratology (Ortho-K), Defocus Incorporated Multiple Segments (DIMS) spectacles, and peripheral progressive addition lenses. Emerging evidence suggests that combination therapy, integrating low-concentration atropine with an optical intervention, may yield superior effects compared to either modality alone. This review also discusses key issues such as treatment personalization, long-term adherence, and future research directions, providing evidence-based insights for clinicians managing childhood myopia.

Keywords

Myopia Control / Low-Concentration Atropine / Orthokeratology / Defocus Incorporated Multiple Segments (DIMS) / Combination Therapy

Cite this article

Download citation ▾
Weixing Xu, Yan Zhang. Advances in Low-Concentration Atropine and Optical Interventions for Myopia Control. Advances in World Medical Research, 2026, 2 (1) : 21-29 DOI:10.71204/h4ject27

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Arumugam, B., & McBrien, N. A. (2012). Muscarinic antagonist control of myopia: Evidence for M4 and M1 receptor-based pathways in the inhibition of experimentally induced axial myopia in the tree shrew. Investigative Ophthalmology & Visual Science, 53, 5827-5837.

[2]

Bullimore, M. A., & Brennan, N. A. (2019). Myopia control: Why each diopter matters. Optometry and Vision Science, 96, 463-465.

[3]

Chia, A., Lu, Q. S., & Tan, D. (2016). Five-year clinical trial on atropine for the treatment of myopia 2: Myopia control with atropine 0.01% eyedrops. Ophthalmology, 123, 391-399.

[4]

Chua, W. H., Balakrishnan, V., Chan, Y. H., Tong, L., Ling, Y., Quah, B. L., & Tan, D. (2006). Atropine for the treatment of childhood myopia. Ophthalmology, 113, 2285-2291.

[5]

Flitcroft, D. I. (2012). The complex interactions of retinal, optical and environmental factors in myopia aetiology. Progress in Retinal and Eye Research, 31, 622-660.

[6]

Holden, B. A., Fricke, T. R., Wilson, D. A., Jong, M., Naidoo, K. S., Sankaridurg, P., Wong, T. Y., Naduvilath, T. J., & Resnikoff, S. (2016). Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology, 123, 1036-1042.

[7]

Jiang, Y., Zhu, Z., Tan, X., Kong, X., Zhong, H., Zhang, J., Xiong, R., Yuan, Y., Zeng, J., Morgan, I. G., & He, M. (2022). Effect of repeated low-level red-light therapy for myopia control in children: A multicenter randomized controlled trial. Ophthalmology, 129, 509-519.

[8]

Lam, C. S. Y., Tang, W. C., Tse, D. Y., Lee, R., P. K., Chun, R. K. M., Hasegawa, K., Qi, H., Hatanaka, T., & To, C. H. (2020). Defocus incorporated multiple segments (DIMS) spectacle lenses slow myopia progression: A 2-year randomised clinical trial. British Journal of Ophthalmology, 104, 363-368.

[9]

Lee, S. H., Tsai, P. C., Chiu, Y. C., Wang, J. H., & Chiu, C. J. (2024). Myopia progression after cessation of atropine in children: A systematic review and meta-analysis. Frontiers in Pharmacology, 15, 1343698.

[10]

Perea-Romero, J., Signes-Soler, I., Badenes-Ribera, L., & Tauste, A. (2025). Efficacy of spectacle lenses specifically designed for myopia control: Systematic review and meta-analysis. Graefe's Archive for Clinical and Experimental Ophthalmology, 263, 909-924.

[11]

Sun, Y., Xu, F., Zhang, T., Liu, M., Wang, D., Chen, Y., & Liu, Q. (2015a). Correction: Orthokeratology to control myopia progression: A meta-analysis. PLoS ONE, 10, e0130646.

[12]

Sun, Y., Xu, F., Zhang, T., Liu, M., Wang, D., Chen, Y., & Liu, Q. (2015b). Orthokeratology to control myopia progression: A meta-analysis. PLoS ONE, 10, e0124535.

[13]

Tan, Q., Ng, A. L., Cheng, G. P., Woo, V. C., & Cho, P., (2019). Combined atropine with orthokeratology for myopia control: Study design and preliminary results. Current Eye Research, 44, 671-678.

[14]

Tedja, M. S., Wojciechowski, R., Hysi, P. G., Eriksson, N., Furlotte, N. A., et al. (2018). Genome-wide association meta-analysis highlights light-induced signaling as a driver for refractive error. Nature Genetics, 50, 834-848.

[15]

Wu, P. C., Chuang, M. N., Choi, J., Chen, H., Wu, G., Ohno-Matsui, K., Jonas, J. B., & Cheung, C. M. G. (2019). Update in myopia and treatment strategy of atropine use in myopia control. Eye, 33, 3-13.

[16]

Xu, S., Wang, M., Qu, Y., Wang, Y., Jiang, J., Zhou, F., Zhao, W., Zheng, B., Chen, W., Lei, X., Li, Z., Hu, Y., & Yang, X. (2025). Twice-daily administration improves the effectiveness of 0.01% atropine for controlling myopia in slowing axial elongation and refractive progression. Ophthalmic and Physiological Optics, 45, 1856-1866.

[17]

Yam, J. C., Jiang, Y., Tang, S. M., Law, A., K. P., Chan, J. J., Wong, E., Ko, S. T., Young, A. L., Tham, C. C., Chen, L. J., & Pang, C. P. (2019). Low-concentration atropine for myopia progression (LAMP) study: A randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology, 126, 113-124.

[18]

Yam, J. C., Li, F. F., Zhang, X., Tang, S. M., Yip, B., H. K., Kam, K. W., Ko, S. T., Young, A. L., Tham, C. C., Chen, L. J., & Pang, C. P. (2020). Two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: Phase 2 report. Ophthalmology, 127, 910-919.

[19]

Yam, J. C., Zhang, X. J., Zaabaar, E., Wang, Y., Gao, Y., Zhang, Y., Li, X., Kam, K. W., Tang, F., Chu, W. K., Zhou, X., Zhang, W., He, X., Wu, P. C., Rose, K. A., Morgan, I., He, M., Ohno-Matsui, K., Jonas, J. B., Zhang, M., Tham, C. C., Chen, L. J., & Pang, C. P. (2025). Interventions to reduce incidence and progression of myopia in children and adults. Progress in Retinal and Eye Research, 109, 101410.

[20]

Yam, J. C., Zhang, X. J., Zhang, Y., Wang, Y. M., Tang, S. M., Li, F. F., Kam, K. W., Ko, S. T., Yip, B., H. K., Young, A. L., Tham, C. C., Chen, L. J., & Pang, C. P. (2022). Three-year clinical trial of low-concentration atropine for myopia progression (LAMP) study: Continued versus washout: Phase 3 report. Ophthalmology, 129, 308-321.

[21]

Zhang, Y., & Wildsoet, C. F. (2015). RPE and choroid mechanisms underlying ocular growth and myopia. Progress in Molecular Biology and Translational Science, 134, 221-240.

[22]

Zheng, N. N., & Tan, K. W. (2022). The synergistic efficacy and safety of combined low-concentration atropine and orthokeratology for slowing the progression of myopia: A meta-analysis. Ophthalmic and Physiological Optics, 42, 1214-1226.

PDF (164KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉